Angiogenesis
Abstract
The formation of new blood and new lymphatic vessels is essential for the growth of the vascular
network. The proliferation and metastatic spread of cancer cells is dependent on an adequate flow
of oxygen, nutrients, and waste products. These new blood and lymph vessels are formed through
the process of angiogenesis, a process regulated by both angiogenesis activator molecules and
angiogenic inhibitor molecules. Over a dozen different angiogenic activating proteins and
inhibitors have been identified. Angiogenic factor levels reflect the level of tumor cell
aggressiveness. Discoveries of angiogenesis inhibitors should help reduce both mortality and
morbidity associated with carcinoma. To date, thousands of patients have been treated with
antiangiogenic therapies. However, their theoretical effectiveness has not been demonstrated in
realworld clinical trials. There is a pressing need for a comprehensive treatment strategy that
combines anti-angiogenesis agents with conventional, but also, therapies to control cancer.
Keywords: angiogenesis, cancer, cells, conditions, development, immune, mechanisms, tumor
Introduction
Cancer is a life-threatening disease that can spread to nearby or distant organs. Tumor
cells can enter the blood or the lymphatic system, travel through the bloodstream, and then
multiply at a different location: metastasis. The growth of a vascular network is essential for the
metastatic distribution of cancer tissue.1 The processes by which new blood and lymphatic
vessels are formed are known as angiogenesis. The process plays an essential role in developing
2
Angiogenesis
the new vascular network that provides nutrients, oxygen, and immune cells and removes waste
products.1 Angiogenic and Lymphangiogenic Factors are increasingly being studied, particularly
in neoplastic Vascularization.1
Tumor Angiogenesis
In studying angiogenesis in healthy settings, researchers may focus on angiogenesis that
predominates in pathological settings. “As a result of these efforts, (1) bioassays for angiogenesis
have been developed; (2)angiogenic factors have been partially or completely purified from
neoplastic and non-neoplastic cells; (3) new polymer technology has been developed for the
sustained release of these factors and other macromolecules in vivo; (4) capillary endothelial
cells have been cloned and cultured for an extended period of time; (5) the modulation of
angiogenesis by nonendothelial cells, or mast cells, which had been demonstrated; (6)
angiogenesis inhibitors recently discovered; and (7) some animal tumors will regress when
angiogenesis is inhibited.” 2 The strongest evidence for the involvement of angiogenesis in tumor
development may come from the actions of angiogenesis inhibitors. It is possible that the first
research to identify the function of angiogenesis in tumor formation may also result in the
development of a new class of pharmaceutical medicines called angiogenesis inhibitors, which
will be used to treat a range of non-neoplastic conditions such psoriasis, arthritis, and ocular
neovascularization.” 3 Nonetheless, there is still a great deal of work to be done to comprehend
the following: the regulatory systems that control capillary density in normal tissues; the
elements that keep microvascular endothelium viable; the vascular system's development; and
the process by which vascular regression happens in both embryonic and postnatal organisms. 4
A knowledge of the mechanisms which underlie these normal processes may help to enlarge our
comprehension of tumor angiogenesis.
3
Angiogenesis
Conclusion
After decades of intensive scientific and clinical study, the use of antiangiogenic medicines in
cancer treatment is on the rise. However, the therapeutic advantages of these medications are quite small.
A deeper comprehension of the molecular and cellular processes controlling tumor angiogenesis and the
reaction to antiangiogenic treatments is probably going to lead to improvements.5 Such advancements are
promised by several recent developments.5 Numerous findings along with others point to ways to enhance
the therapeutic advantages of antiangiogenic treatment. Creating more accurate preclinical models to
research the biology of tumor angiogenesis and antiangiogenic treatments are two of these tactics.6 These
advancements will also be crucial for the long-term antiangiogenic treatment that patients with early-stage
illness receive as an adjuvant.6 Regarding the management of metastatic illness, the scope and variety of
targets for antiangiogenic strategies indicate a plethora of potential antiangiogenic medication
combinations that ought to be far more efficacious than cancer treatment in isolation.
PLACEHOLDER.1
References
1. Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences,
challenges and opportunities. Cell Mol Life Sci. 2020 May;77(9):1745-1770. doi:
10.1007/s00018-019-03351-7. Epub 2019 Nov 6. PMID: 31690961; PMCID: PMC7190605.
2. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2019 May 8;358(19):2039-49. doi:
10.1056/NEJMra0706596. PMID: 18463380; PMCID: PMC4542009.
3. Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences,
challenges and opportunities. Cell Mol Life Sci. 2020 May;77(9):1745-1770. doi:
10.1007/s00018-019-03351-7. Epub 2019 Nov 6. PMID: 31690961; PMCID: PMC7190605.
4
Angiogenesis
4. Ziyad S, Iruela-Arispe ML. Molecular mechanisms of tumor angiogenesis. Genes Cancer.
2019 Dec;2(12):1085-96. doi: 10.1177/1947601911432334. PMID: 22866200; PMCID:
PMC3411131.
5. Mendelsohn, John, et al. The Molecular Basis of Cancer. 4th ed. Philadelphia, PA: W.B.
Saunders Co.; 2015. ISBN: 9781455740666.
6. Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z, Li X, Cao K, Deng H, He Y, Liao Q,
Xiang B, Zhou M, Guo C, Zeng Z, Li G, Li X, Xiong W. The role of microenvironment in
tumor angiogenesis. J Exp Clin Cancer Res. 2020 Sep 30;39(1):204. doi:
10.1186/s13046020-01709-5. PMID: 32993787; PMCID: PMC7526376.
Appendix
"Add content here or delete this page if not needed"
5
Powered by TCPDF (www.tcpdf.org)
